Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (2557)	11/17/2005 5:18:09 PM
From: software salesperson	Respond to of 3044

Should have been added to my previous post: (xii) 518 - -front line AML as single agent and in combo with standard chemo; agreement with CTEP, a branch of NCI, to explore potential of 518 as single agent and in combo in glioblastoma, prostate cancer and renal cell carcinoma; this approach is similar to what was done with V possible near-term valuation events: Possible joint development deal - - Deborah’s next priority V ASH december data - - investigator-initiated front line mm and updated phase 3 apex survival data; there have been 50 V abstracts accepted how many salespeople will you have after the increase? - - full deployment of just under 100 by 1/06 ( effect to be seen in 1 q ’06) Interim V data for relapsed follicular lymphoma at Ash (?) data on V in ovarian and prostate cancers will be available by year end (?) sales